Additional Relevant Details Roche's drug atezolizumab is the foundation of its cancer immunotherapy portfolio, which it is massively expanding with many combination treatments for various forms of cancer.  In 2016, Roche expects 11 Phase 1b readouts, as well as a few Phase 2 and one Phase 3 readout.  Based off the Phase 1b trials, Roche will determine which combination treatments to advance to late-stage studies.